CR9521A - Metodo novedoso de tratamiento de la hiperlipedemia - Google Patents

Metodo novedoso de tratamiento de la hiperlipedemia

Info

Publication number
CR9521A
CR9521A CR9521A CR9521A CR9521A CR 9521 A CR9521 A CR 9521A CR 9521 A CR9521 A CR 9521A CR 9521 A CR9521 A CR 9521A CR 9521 A CR9521 A CR 9521A
Authority
CR
Costa Rica
Prior art keywords
treatment
hyperlipedemia
new method
hmg
hyperlipidemia
Prior art date
Application number
CR9521A
Other languages
English (en)
Inventor
Nishimoto Tomoyuki
Tozama Ryiuchi
Wada Takeo
Ishikawa Elichiro
Nishi Toshiya
Yamakawa Hiroko
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of CR9521A publication Critical patent/CR9521A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se provee una composicion farmaceutica util para prevencion y/o tratamiento de hiperlipidemia que comprende la combinacion de una cantidad eficaz de inhibidor de escualeno sintasa y un inhibidor de HMG-CoA reductasa.
CR9521A 2005-06-01 2007-11-15 Metodo novedoso de tratamiento de la hiperlipedemia CR9521A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68587105P 2005-06-01 2005-06-01
US72832905P 2005-10-20 2005-10-20

Publications (1)

Publication Number Publication Date
CR9521A true CR9521A (es) 2008-02-22

Family

ID=36699172

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9521A CR9521A (es) 2005-06-01 2007-11-15 Metodo novedoso de tratamiento de la hiperlipedemia

Country Status (17)

Country Link
US (1) US20090209510A1 (es)
EP (1) EP1962832A2 (es)
JP (1) JP2008542191A (es)
KR (1) KR20080012916A (es)
AR (1) AR054368A1 (es)
AU (1) AU2006253255A1 (es)
BR (1) BRPI0610484A2 (es)
CA (1) CA2609784A1 (es)
CR (1) CR9521A (es)
IL (1) IL187207A0 (es)
MA (1) MA29531B1 (es)
MX (1) MX2007014730A (es)
NO (1) NO20076566L (es)
PE (1) PE20070603A1 (es)
RU (1) RU2007149337A (es)
TW (1) TW200714280A (es)
WO (1) WO2006129859A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI407955B (zh) 2007-03-29 2013-09-11 Kowa Co 高脂血症之預防及／或治療劑
MY157189A (en) * 2008-01-10 2016-05-13 Takeda Pharmaceutical Capsule formulation
US9541565B2 (en) 2011-04-08 2017-01-10 Zora Biosciences Oy Biomarkers for sensitive detection of statin-induced muscle toxicity
JP5980900B2 (ja) 2011-04-08 2016-08-31 ゾラ バイオサイエンシーズ オサケ ユキチュア スタチン誘発性筋毒性の高感度検出のためのバイオマーカー
RU2543485C2 (ru) * 2013-02-26 2015-03-10 Андрей Александрович Иващенко Гетероциклические агонисты рецепторов желчных кислот tgr5, фармацевтическая композиция, способы их получения и применения
US11833133B2 (en) 2020-08-13 2023-12-05 Orient Pharma Co., Ltd. Solid oral pharmaceutical composition
TWI760067B (zh) * 2020-08-13 2022-04-01 友霖生技醫藥股份有限公司 固態口服醫藥組成物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4929437A (en) * 1989-02-02 1990-05-29 Merck & Co., Inc. Coenzyme Q10 with HMG-CoA reductase inhibitors
CA2007643A1 (en) * 1989-02-01 1990-08-01 Donald S. Karanewsky Combination of an hmg coa reductase inhibitor and a squalene synthetase inhibitor and method for lowering serum cholesterol using such combination
AU5140993A (en) * 1992-10-06 1994-04-26 Merck & Co., Inc. Zaragozic acid derivatives and methods of treating hypercholesterolemia, fungal growth, and cancer therewith
RU2040932C1 (ru) * 1993-12-17 1995-08-09 Крестьянское хозяйство "Агрофирма Дижа" Препарат, влияющий на тканевой обмен и применение штамма гриба fusarium sambucinum fuckel var ossicolum (berk.et curf) bilai для его получения
JP3479796B2 (ja) * 1995-09-13 2003-12-15 武田薬品工業株式会社 ベンゾオキサゼピン化合物
CN1072649C (zh) * 1995-09-13 2001-10-10 武田药品工业株式会社 苯并氧杂吖庚因化合物,其生产方法和用途
WO1997048701A1 (en) * 1996-06-20 1997-12-24 Pfizer Inc. 4,1-benzoxazepines or 4,1-benzothiazepines and their use as squalene synthetase inhibitors
HUP0301301A2 (hu) * 2000-06-23 2003-08-28 Takeda Chemical Industries Ltd. Benzoxazepinon-származékok és szkvalén szintáz inhibitorként való alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
CN1473053A (zh) * 2000-11-09 2004-02-04 ����ҩƷ��ҵ��ʽ���� 高密度脂蛋白-胆甾醇含量提高剂
ATE253353T1 (de) * 2001-04-12 2003-11-15 Vesifact Ag Coenzym q10 enthaltende mikroemulsion- prekonzentrate und mikroemulsionen
EP1407782A4 (en) * 2001-06-28 2004-10-20 Takeda Chemical Industries Ltd AGENTS FOR PREVENTION / TREATMENT OF FUNCTIONAL ORGANIC DISEASES AND ORGANIC DYSFUNCTION
CA2513170A1 (en) * 2003-01-17 2004-08-05 Takeda Pharmaceutical Company Limited Skeletal muscle protecting agent

Also Published As

Publication number Publication date
JP2008542191A (ja) 2008-11-27
US20090209510A1 (en) 2009-08-20
RU2007149337A (ru) 2009-07-10
MA29531B1 (fr) 2008-06-02
AU2006253255A1 (en) 2006-12-07
MX2007014730A (es) 2008-02-15
TW200714280A (en) 2007-04-16
WO2006129859A3 (en) 2007-04-19
CA2609784A1 (en) 2006-12-07
NO20076566L (no) 2008-02-22
WO2006129859A2 (en) 2006-12-07
IL187207A0 (en) 2008-06-05
AR054368A1 (es) 2007-06-20
EP1962832A2 (en) 2008-09-03
PE20070603A1 (es) 2007-06-22
KR20080012916A (ko) 2008-02-12
BRPI0610484A2 (pt) 2017-01-31

Similar Documents

Publication Publication Date Title
BRPI0413363A (pt) formas de dosagem fornecendo liberação controlada de inibidores de proteìna de transferência de ésteres de colesterila e liberação imediata de inibidores de hmg-coa redutase
CL2007001325A1 (es) Compuestos derivados de biciclos, inhibidores de cept; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar hiperlipidemia, arterioesclerosis, entre otras enfermedades.
CL2007002686A1 (es) Compuestos derivados de 2h-isoquinolin-1-ona y 3h-quinazolin-4-ona, inhibidores de cinasa rho; y composicion farmaceutica, util para el tratamiento de una enfermedad o afeccion cardiovascular.
PA8846901A1 (es) Inhibidores de cinasa akt y p70 s6.
TW200510002A (en) Solid pharmaceutical preparation
BRPI0709769B8 (pt) implantes biodegradáveis para o tratamento de estados associados à dopamina
BRPI0718661A2 (pt) Método para prevenir o crescimento de microorganismos, e uma combinação para a prevenção do crescimento microbiano
TW200638950A (en) Dosage forms of cholesteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
PL2034985T3 (pl) POŁĄCZENIE INHIBITORA REDUKTAZY HMG-CoA I INHIBITORA SYNTAZY PIROFOSFATAZY FARNEZYLU W LECZENIU CHORÓB ZWIĄZANYCH Z UTRZYMYWANIEM SIĘ I/ LUB AKUMULACJĄ BIAŁEK PRENYLOWANYCH
NO20076566L (no) Ny fremgangsmate for behandling av hyperlipidemi
EA200900073A1 (ru) КОМБИНАЦИЯ ИНГИБИТОРОВ HMG-CoA-РЕДУКТАЗЫ И ИНГИБИТОРОВ ФОСФОДИЭСТЕРАЗЫ 4, ПРЕДНАЗНАЧЕННАЯ ДЛЯ ЛЕЧЕНИЯ ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ ЛЕГКИХ
WO2003057205A3 (de) KOMBINATION VON MTP INHIBITOREN ODER apoB-SEKRETIONS-INHIBITOREN MIT FIBRATEN ZUR VERWENDUNG ALS ARZNEIMITTEL
ZA200806937B (en) Combination of triazine derivatives and HMG-CoA reductase inhibitors for the treatment of diabetes
PA8464601A1 (es) Combinaciones de estatina-eter carboxialquilico
CY1111768T1 (el) Νεος παραγοντας μειωσης τριγλυκεριδιου
BRPI0509926A (pt) imidazóis
UY28653A1 (es) N-alquil pirroles como inhibidores de la hmg-coa reductasa
EP1812019A4 (en) COMBINATION OF POLYCHITOSAMINE AND HMG-COA REDUCTASE INHIBITOR FOR THE TREATMENT OF HYPERLIPIDEMIA
DK1879862T3 (da) Magnesiumsalte af HMG-COA reduktaseinhibitorer
GR20050100466A (el) Βελτιωμενες φαρμακευτικες συνθεσεις που περιεχουναναστολεις της αναγωγασης του 3-υδροξυ-3-μεθυλογλουταρυλοσυνενζυμου α (hmg-coa) και μεθοδος παρασκευης αυτων
CL2008000170A1 (es) Sal estroncica de atorvastatina, o sus hidratos o polimorfos; metodo de preparacion; composicion farmaceutica, util para la prevencion o tratamiento de hiperlipidemia e hipercolesterolemia.
EP1871396A4 (en) STABILIZED PHARMACEUTICAL COMPOSITIONS WITH AN HMG COA REDUCTASE INHIBITOR
BRPI0614810A2 (pt) combinação de compostos orgánicos
BRPI0813174A2 (pt) Composição farmacêutica que compreende a combinação de um agente inibidor da enzima hmg-coa redutase e um agente inibidor da enzima lipase gastrointestinal
WO2005091804A3 (en) Paramyxovirus family inhibitors and methods of use thereof

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)